← Leaderboards
Joan Weinberger Berman
Yeshiva University
$30,689,484
Attributed
$43,759,526
Total exposure
20
Grants
16
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $3.5M · FY2005–25$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$43,759,526 · 20
By mechanism
R01$36,343,630 · 12
P30$4,905,466 · 4
P50$1,245,456 · 1
R21$915,750 · 2
P20$349,224 · 1
Top collaborators
- Harris Goldstein12 shared
- David J Volsky10 shared
- Susan Morgello6 shared
- Vilma Gabbay4 shared
- Jennifer L Kelschenbach4 shared
- Anjali Sharma4 shared
- Leah Helane Rubin2 shared
- Rebecca Terilli Veenhuis2 shared
Others in their field
Top investigators on “Cells”
- Lawrence Corey · Fred Hutchinson Cancer Center$536,344,731
- Barton F Haynes · Duke University$457,457,619
- David Heimbrook · Leidos Biomedical Research, Inc.$454,789,509
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$299,104,942
- Dennis R. Burton · Scripps Research Institute$278,781,854
- Mary M Horowitz · Medical College Of Wisconsin$237,383,608
Research focus
CellsChemokineBrainHiv InfectionsMonocyteMediatingMacrophageInflammationProteinsAntiretroviral TherapyCcl2 GeneBlood - Brain Barrier AnatomyViralIn VitroResponseInfectionPathogenesisAstrocytesNeuroinflammationNeuropathogenesisChronicLifeCytokineNeurons
Grant awards (100)
Immune mechanisms that shape the blood brain barrier in people living with HIV and cocaine use disorder$1,039,343
R01 · FY2025 · DA
Effect of buprenorphine on monocytes in the context of neuroAids and opioid abuse$754,025
R01 · FY2025 · DA · contact PI
Inflammation, BBB disruption, and Reward Function in the Pathogenesis of Depression among PWH$603,301
R01 · FY2025 · MH
The impact of methamphetamine on CXCL12 mediated HIV neuropathogenesis$420,000
R01 · FY2025 · DA · contact PI
ERC Einstein Rockefeller CUNY Center for AIDS Research$375,000
P30 · FY2025 · AI · contact PI
Immune mechanisms that shape the blood brain barrier in people living with HIV and cocaine use disorder$1,057,519
R01 · FY2024 · DA
Effect of buprenorphine on monocytes in the context of neuroAids and opioid abuse$754,413
R01 · FY2024 · DA · contact PI
Inflammation, BBB disruption, and Reward Function in the Pathogenesis of Depression among PWH$632,077
R01 · FY2024 · MH
The impact of methamphetamine on CXCL12 mediated HIV neuropathogenesis$420,000
R01 · FY2024 · DA · contact PI
ERC Einstein Rockefeller CUNY Center for AIDS Research$306,936
P30 · FY2024 · AI · contact PI
Mechanisms of opioid- mediated HIV neuropathogenesis$834,068
R01 · FY2023 · DA · contact PI
Effect of buprenorphine on monocytes in the context of neuroAids and opioid abuse$761,502
R01 · FY2023 · DA · contact PI
Inflammation, BBB disruption, and Reward Function in the Pathogenesis of Depression among PWH$754,485
R01 · FY2023 · MH
The impact of methamphetamine on CXCL12 mediated HIV neuropathogenesis$420,000
R01 · FY2023 · DA · contact PI
ERC Einstein Rockefeller CUNY Center for AIDS Research$359,608
P30 · FY2023 · AI · contact PI
Inflammation, BBB disruption, and Reward Function in the Pathogenesis of Depression among PWH$844,635
R01 · FY2022 · MH
Mechanisms of opioid- mediated HIV neuropathogenesis$834,068
R01 · FY2022 · DA · contact PI
Effect of buprenorphine on monocytes in the context of neuroAids and opioid abuse$785,684
R01 · FY2022 · DA · contact PI
The impact of methamphetamine on CXCL12 mediated HIV neuropathogenesis$420,000
R01 · FY2022 · DA · contact PI
ERC Einstein Rockefeller CUNY Center for AIDS Research$334,051
P30 · FY2022 · AI · contact PI
Mechanisms of opioid- mediated HIV neuropathogenesis$834,068
R01 · FY2021 · DA · contact PI
Impact of illicit drugs, HIV, and ART on neuroinflammation and BBB disruption$752,263
R01 · FY2021 · DA · contact PI
Monocyte CNS HIV entry & neurodegeneration: Translational studies in the CART era$731,703
R01 · FY2021 · MH · contact PI
Effect of buprenorphine on monocytes in the context of neuroAids and opioid abuse$716,442
R01 · FY2021 · DA · contact PI
Biomarkers Advance Technology Core$461,662
P30 · FY2021 · AI · contact PI
Mechanisms of opioid- mediated HIV neuropathogenesis$834,068
R01 · FY2020 · DA · contact PI
Impact of illicit drugs, HIV, and ART on neuroinflammation and BBB disruption$754,479
R01 · FY2020 · DA · contact PI
Monocyte CNS HIV entry & neurodegeneration: Translational studies in the CART era$734,726
R01 · FY2020 · MH · contact PI
Effect of buprenorphine on monocytes in the context of neuroAids and opioid abuse$719,921
R01 · FY2020 · DA · contact PI
Biomarkers Advance Technology Core$470,090
P30 · FY2020 · AI · contact PI
Mechanisms of opioid- mediated HIV neuropathogenesis$834,068
R01 · FY2019 · DA · contact PI
Impact of illicit drugs, HIV, and ART on neuroinflammation and BBB disruption$756,652
R01 · FY2019 · DA · contact PI
Monocyte CNS HIV entry & neurodegeneration: Translational studies in the CART era$734,726
R01 · FY2019 · MH · contact PI
Effect of buprenorphine on monocytes in the context of neuroAids and opioid abuse$723,314
R01 · FY2019 · DA · contact PI
Biomarkers Advance Technology Core$254,310
P30 · FY2019 · AI · contact PI
Impact of illicit drugs, HIV, and ART on neuroinflammation and BBB disruption$158,650
R01 · FY2019 · DA · contact PI
Effect of buprenorphine on monocytes in the context of neuroAids and opioid abuse$586,232
R01 · FY2018 · DA · contact PI
Impact of illicit drugs, HIV, and ART on neuroinflammation and BBB disruption$514,958
R01 · FY2018 · DA · contact PI
Monocyte CNS HIV entry & neurodegeneration: Translational studies in the CART era$490,564
R01 · FY2018 · MH · contact PI
Biomarkers Advance Technology Core$353,717
P30 · FY2018 · AI · contact PI
Monocyte CNS HIV entry & neurodegeneration: Translational studies in the CART era$244,162
R01 · FY2018 · MH · contact PI
Impact of illicit drugs, HIV, and ART on neuroinflammation and BBB disruption$243,823
R01 · FY2018 · DA · contact PI
Biomarkers Advance Technology Core$205,527
P30 · FY2018 · AI · contact PI
Effect of buprenorphine on monocytes in the context of neuroAids and opioid abuse$140,389
R01 · FY2018 · DA · contact PI
Impact of illicit drugs, HIV, and ART on neuroinflammation and BBB disruption$834,993
R01 · FY2017 · DA · contact PI
Monocyte CNS HIV entry & neurodegeneration: Translational studies in the CART era$751,476
R01 · FY2017 · MH · contact PI
Effect of buprenorphine on monocytes in the context of neuroAids and opioid abuse$730,959
R01 · FY2017 · DA · contact PI
Biomarkers Advance Technology Core$246,721
P30 · FY2017 · AI · contact PI
Mechanisms of HAD:Role of CCL2 BBB & HIV Infection$239,441
R01 · FY2016 · MH · contact PI
Mechanisms of HAD:Role of CCL2 BBB & HIV Infection$285,401
R01 · FY2015 · MH · contact PI
Role of cellular prion protein in the pathogenesis of NeuroAIDS$206,394
R01 · FY2015 · MH · contact PI
Role of cellular prion protein in the pathogenesis of NeuroAIDS$187,856
R01 · FY2015 · MH · contact PI
Mechanisms of HIV Tat regulation of macrophage gene expression in neuroAIDS$116,112
R21 · FY2015 · MH · contact PI
Mechanisms of HIV Tat regulation of macrophage gene expression in neuroAIDS$92,638
R21 · FY2015 · MH · contact PI
Mechanisms of HAD:Role of CCL2 BBB & HIV Infection$90,349
R01 · FY2015 · MH · contact PI
Role of cellular prion protein in the pathogenesis of NeuroAIDS$394,250
R01 · FY2014 · MH · contact PI
Mechanisms of HAD:Role of CCL2 BBB & HIV Infection$375,750
R01 · FY2014 · MH · contact PI
Mechanisms of HIV Tat regulation of macrophage gene expression in neuroAIDS$250,500
R21 · FY2014 · MH · contact PI
Role of cellular prion protein in the pathogenesis of NeuroAIDS$378,480
R01 · FY2013 · MH · contact PI
Mechanisms of HAD:Role of CCL2 BBB & HIV Infection$360,720
R01 · FY2013 · MH · contact PI
Immunology/Pathology Core$200,035
P30 · FY2013 · AI · contact PI
Role of cellular prion protein in the pathogenesis of NeuroAIDS$394,250
R01 · FY2012 · MH · contact PI
Mechanisms of HAD:Role of CCL2 BBB & HIV Infection$375,563
R01 · FY2012 · MH · contact PI
Immunology/Pathology Core$350,519
P30 · FY2012 · AI · contact PI
Dopamine alters CNS migration of uninfected and HIV infected leukocytes to SDF-1$338,746
R01 · FY2012 · DA · contact PI
Role of cellular prion protein in the pathogenesis of NeuroAIDS$385,472
R01 · FY2011 · MH · contact PI
Mechanisms of HAD:Role of CCL2 BBB & HIV Infection$364,590
R01 · FY2011 · MH · contact PI
Dopamine alters CNS migration of uninfected and HIV infected leukocytes to SDF-1$338,746
R01 · FY2011 · DA · contact PI
Immunology/Pathology Core$286,439
P30 · FY2011 · AI · contact PI
Effects of Buprenorphine on Monocytes and the BBB: Implications for NeuroAIDS$115,435
P20 · FY2011 · DA · contact PI
Mechanisms of HAD: Role of CCL2, BBB and HIV infection$382,818
R01 · FY2010 · MH · contact PI
Dopamine alters CNS migration of uninfected and HIV infected leukocytes to SDF-1$349,223
R01 · FY2010 · DA · contact PI
Immunology/Pathology Core$208,961
P30 · FY2010 · AI · contact PI
Effects of Buprenorphine on Monocytes and the BBB: Implications for NeuroAIDS$119,794
P20 · FY2010 · DA · contact PI
Mechanisms of HAD: Role of CCL2, BBB and HIV infection$382,818
R01 · FY2009 · MH · contact PI
Dopamine alters CNS migration of uninfected and HIV infected leukocytes to SDF-1$352,750
R01 · FY2009 · DA · contact PI
Immunology/Pathology Core$235,719
P30 · FY2009 · AI · contact PI
Role of soluble CD40L as a predictor of HIV CNS impairment$207,500
R21 · FY2009 · MH · contact PI
Effects of Buprenorphine on Monocytes and the BBB: Implications for NeuroAIDS$113,995
P20 · FY2009 · DA · contact PI
Mechanisms of HIV Tat neurotoxicity and CCL2 protection$395,865
R01 · FY2008 · MH · contact PI
Mechanisms of HAD: Role of CCL2, BBB and HIV infection$382,818
R01 · FY2008 · MH · contact PI
Dopamine alters CNS migration of uninfected and HIV infected leukocytes to SDF-1$352,750
R01 · FY2008 · DA · contact PI
Immunology/Pathology Core$256,171
P30 · FY2008 · AI · contact PI
Role of soluble CD40L as a predictor of HIV CNS impairment$249,000
R21 · FY2008 · MH · contact PI
Mechanisms of HIV Tat neurotoxicity and CCL2 protection$395,865
R01 · FY2007 · MH · contact PI
Mechanisms of HAD: Role of CCL2, BBB and HIV infection$382,818
R01 · FY2007 · MH · contact PI
Mechanisms of HIV Tat neurotoxicity and CCL2 protection$407,689
R01 · FY2006 · MH · contact PI
Mechanisms of HAD: Role of CCL2, BBB and HIV infection$393,459
R01 · FY2006 · MH · contact PI
Mechanisms of HIV Tat neurotoxicity and CCL2 protection$417,500
R01 · FY2005 · MH
Mechanisms of HIV Tat neurotoxicity and CCL2 protection$56,032
R01 · FY2005 · MH
Mechanisms of HIV Tat neurotoxicity and CCL2 protection$412,974
R01 · FY2004 · MH
Interaction of HIV1 with the vascular endothelium$250,500
R01 · FY2004 · MH
Interaction of HIV1 with the vascular endothelium$250,500
R01 · FY2003 · MH
Regulation of leukocyte trafficking at the BBB$311,364
P50 · FY2002 · NS
INTERACTION OF HIV1 WITH THE VASCULAR ENDOTHELIUM$117,574
R01 · FY2002 · MH
INTERACTION OF HIV1 WITH THE VASCULAR ENDOTHELIUM$354,783
R01 · FY2001 · MH
Regulation of leukocyte trafficking at the BBB$311,364
P50 · FY2001 · NS
INTERACTION OF HIV1 WITH THE VASCULAR ENDOTHELIUM$431,130
R01 · FY2000 · MH
Regulation of leukocyte trafficking at the BBB$311,364
P50 · FY2000 · NS
Regulation of leukocyte trafficking at the BBB$311,364
P50 · FY2000 · NS